By Chris Wack


Lipella Pharmaceuticals Inc. shares were up 76% at $5.48 after the company said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.

The stock, which had its initial public offering on Dec. 20, hit its low of $2.87 on Jan. 3.

The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study's results and the pathway forward to seeking regulatory approval for LP-10.

The study recruited 13 subjects with moderate to severe refractory hemorrhagic cystitis. These subjects were treated with up to two courses of LP-10 intravesical bladder instillations.

All subjects tolerated the LP-10 instillations and completed the study without report of product-related serious adverse events. LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake, decreased cystoscopic bleeding and ulceration sites, and improved patients' urinary symptoms.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-11-23 1030ET